Stroke Trials Registry

BMS-204352
MaxiPost®

Action
Activates neuronal potassium channels, may result in neuronal hyperpolarization or decreased neurotransmitter release.

Status
Bristol-Meyers Squibb announced 1/24/01 that BMS-204352 failed to show efficacy in a phase III multicenter trial. A second trial is considered.

Trial(s)
= Ongoing
= Completed

POST-010 and POST-011 Potassium-channel Opening Stroke Trial

Web Links and Publications

Bristol-Myers Squibb Web Site.

Post-011: Efficacy and Safety of MaxiPostTM in Patients with Acute Stroke. XVII World Congress of Neurology.
JNS Volume 187, Supplement 1, page S255, June 2001.

POST: Double-Blind, Placebo Controlled, Safety and Efficacy Trials of Intravenous BMS-204352 in Patients with Acute Stroke. Ongoing Clinical Trials Session, 25th International Stroke Conference.
Ongoing Clinical Trials Session, 25th International Stroke Conference.

POST: An MRI Substudy of A Double-Blind, Placebo Controlled, Safety and Efficacy Trial of Intravenous BMS-204352 in Patients with Acute Stroke. On-going Clinical Trials Session, 25th International Stroke Conference.
Ongoing Clinical Trials Session, 25th International Stroke Conference.

UID: 53